Biotech Values

[DewDiligence]

EXAS—(+27%)—raised 2017 guidance big-league:

http://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2017/Cologuard-growth-accelerates-to-484-million-in-revenue-during-first-quarter-volume-grows-150-percent-year-over-year-to-100000-completed-tests/default.aspx

• Revenue guidance raised to $195-205 million for 2017, from $170-180 million [the prior 2017 guidance];

• Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000 [the prior 2017 guidance].

Although EXAS is not yet profitable, the business is slowly but surely growing into the stock’s (somewhat lofty) valuation. I think Cologuard is a fine product.